Biodesix, Inc. last reported quarterly results on Aug 5, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $26.9 million (+34.2% year over year) and diluted EPS of -$0.71. It usually reports 34–57 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 2, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Monday. Based on last year's release for the same quarter on Nov 3, 2025. The company has not filed these results with the SEC yet. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 34–57 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 5, 2026
36 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
27
+34.2%
|
-7
+36.6%
|
-0.71
+54.5%
|
|
May 4, 2026
34 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
26
+42.3%
|
-8
+29.8%
|
-0.81
+46.7%
|
|
Feb 26, 2026
57 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
29
+40.8%
|
-4
+51.8%
|
-0.49
+56.2%
|
|
Nov 3, 2025
34 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
22
+19.9%
|
-9
+15.0%
|
-1.16
+17.1%
|
|
Aug 7, 2025
38 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
20
+11.7%
|
-11
-6.1%
|
-1.56
-1850.0%
|
|
May 13, 2025
43 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
18
+21.2%
|
-11
+18.5%
|
-1.52
-985.7%
|
|
Jan 10, 2025
10 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
20
+39.3%
|
-8
+9.7%
|
-1.13
-1037.5%
|
|
Nov 1, 2024
32 days after quarter end
|
—
ended Sep 30, 2024
|
—
|
—
|
—
|
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- BDSX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Louisville, CO
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1439725
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.